Cargando…

Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia

BACKGROUND: Transient hypothyroxinemia of prematurity (THOP) is defined as a low level of circulating thyroxine (T4), despite low or normal thyroid-stimulating hormone (TSH) levels. Aims: We aimed to evaluate the incidence of THOP, the clinical and laboratory findings of preterm infants with this co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Aslan, Ozer, Yavuz, Kaya, Nesrin, Cakir, Aydilek Dagdeviren, Culpan, Hazal Cansu, Perk, Yildiz, Vural, Mehmet, Evliyaoglu, Olcay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466863/
https://www.ncbi.nlm.nih.gov/pubmed/37644575
http://dx.doi.org/10.1186/s13052-023-01516-6
_version_ 1785098985826942976
author Yilmaz, Aslan
Ozer, Yavuz
Kaya, Nesrin
Cakir, Aydilek Dagdeviren
Culpan, Hazal Cansu
Perk, Yildiz
Vural, Mehmet
Evliyaoglu, Olcay
author_facet Yilmaz, Aslan
Ozer, Yavuz
Kaya, Nesrin
Cakir, Aydilek Dagdeviren
Culpan, Hazal Cansu
Perk, Yildiz
Vural, Mehmet
Evliyaoglu, Olcay
author_sort Yilmaz, Aslan
collection PubMed
description BACKGROUND: Transient hypothyroxinemia of prematurity (THOP) is defined as a low level of circulating thyroxine (T4), despite low or normal thyroid-stimulating hormone (TSH) levels. Aims: We aimed to evaluate the incidence of THOP, the clinical and laboratory findings of preterm infants with this condition and the levothyroxine (L-T4) treatment. METHODS: Preterm infants (n = 181) delivered at 24–34 weeks of gestation were evaluated by their thyroid function tests that were performed between the 10(th) and 20(th) days of postnatal life and interpreted according to the gestational age (GA) references. Clinical and laboratory characteristics of the patients with THOP and normal thyroid function tests were compared. Patients with THOP and treated with L-T4 were compared with the ones who were not regarding laboratory, and clinical characteristics. RESULTS: Incidence of hypothyroxinemia of prematurity was 45.8% (n = 83). Euthyroidism, primary hypothyroidism, and subclinical hypothyroidism were diagnosed in 47.5% (n = 86), 5% (n = 9) and 1.7% (n = 3) of the patients, respectively. Mean birth weight (BW) and GA were significantly lower in the hypothyroxinemia group than in the euthyroid group (p < 0.001). L-T4 was started in 43% (n = 36) of the patients with THOP. Treatment initiation rate was 44.4% (n = 16) in 24–27 wk, 41.6% (n = 15) in 28–30 wk, and 13.8% (n = 5) in 31–34 wk. As the GA increased, the incidence of THOP and the rate of treatment initiation decreased (p < 0.001). The lowest free thyroxine (FT4) cut-off value was 0.72 ng/dl in the treated group. In addition, incidences of vancomycin + amikacin, caffeine, dopamine treatments, RDS, IVH, BPD, central catheter, FFP transfusion, and ventilator support were higher in the treated group (P < 0.05). CONCLUSION: This study revealed that prevalence of THOP increased as the GA and BW decreased. As the GA decreased, THOP patients requiring L-T4 treatment increased. Additionally, association with comorbid diseases increased the requirement of treatment.
format Online
Article
Text
id pubmed-10466863
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104668632023-08-31 Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia Yilmaz, Aslan Ozer, Yavuz Kaya, Nesrin Cakir, Aydilek Dagdeviren Culpan, Hazal Cansu Perk, Yildiz Vural, Mehmet Evliyaoglu, Olcay Ital J Pediatr Research BACKGROUND: Transient hypothyroxinemia of prematurity (THOP) is defined as a low level of circulating thyroxine (T4), despite low or normal thyroid-stimulating hormone (TSH) levels. Aims: We aimed to evaluate the incidence of THOP, the clinical and laboratory findings of preterm infants with this condition and the levothyroxine (L-T4) treatment. METHODS: Preterm infants (n = 181) delivered at 24–34 weeks of gestation were evaluated by their thyroid function tests that were performed between the 10(th) and 20(th) days of postnatal life and interpreted according to the gestational age (GA) references. Clinical and laboratory characteristics of the patients with THOP and normal thyroid function tests were compared. Patients with THOP and treated with L-T4 were compared with the ones who were not regarding laboratory, and clinical characteristics. RESULTS: Incidence of hypothyroxinemia of prematurity was 45.8% (n = 83). Euthyroidism, primary hypothyroidism, and subclinical hypothyroidism were diagnosed in 47.5% (n = 86), 5% (n = 9) and 1.7% (n = 3) of the patients, respectively. Mean birth weight (BW) and GA were significantly lower in the hypothyroxinemia group than in the euthyroid group (p < 0.001). L-T4 was started in 43% (n = 36) of the patients with THOP. Treatment initiation rate was 44.4% (n = 16) in 24–27 wk, 41.6% (n = 15) in 28–30 wk, and 13.8% (n = 5) in 31–34 wk. As the GA increased, the incidence of THOP and the rate of treatment initiation decreased (p < 0.001). The lowest free thyroxine (FT4) cut-off value was 0.72 ng/dl in the treated group. In addition, incidences of vancomycin + amikacin, caffeine, dopamine treatments, RDS, IVH, BPD, central catheter, FFP transfusion, and ventilator support were higher in the treated group (P < 0.05). CONCLUSION: This study revealed that prevalence of THOP increased as the GA and BW decreased. As the GA decreased, THOP patients requiring L-T4 treatment increased. Additionally, association with comorbid diseases increased the requirement of treatment. BioMed Central 2023-08-29 /pmc/articles/PMC10466863/ /pubmed/37644575 http://dx.doi.org/10.1186/s13052-023-01516-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yilmaz, Aslan
Ozer, Yavuz
Kaya, Nesrin
Cakir, Aydilek Dagdeviren
Culpan, Hazal Cansu
Perk, Yildiz
Vural, Mehmet
Evliyaoglu, Olcay
Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title_full Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title_fullStr Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title_full_unstemmed Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title_short Clinical indicators that influence a clinician’s decision to start L-thyroxine treatment in prematurity with transient hypothyroxinemia
title_sort clinical indicators that influence a clinician’s decision to start l-thyroxine treatment in prematurity with transient hypothyroxinemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466863/
https://www.ncbi.nlm.nih.gov/pubmed/37644575
http://dx.doi.org/10.1186/s13052-023-01516-6
work_keys_str_mv AT yilmazaslan clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT ozeryavuz clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT kayanesrin clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT cakiraydilekdagdeviren clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT culpanhazalcansu clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT perkyildiz clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT vuralmehmet clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia
AT evliyaogluolcay clinicalindicatorsthatinfluenceacliniciansdecisiontostartlthyroxinetreatmentinprematuritywithtransienthypothyroxinemia